FDA Considerations for the Labeling and Future Trials - Andrew Farb

Overview

FDA Considerations for the Labeling and Future Trials - Andrew Farb

Who Should I Refer for PFO Closure and What Studies I Would Like to See - The Neurologist Perspective - Richard Benson

Now Approved, How Do We Utilize It - Cardiology Perspective - Jon Resar

PFO Closure - Industry Perspective - Dan Gutfinger

Lessons From WATCHMAN Launch: FDA, CMS, and the Launch of a New Therapy - Kenneth Stein, MD

LAA Occlusion Post-Approval Studies: Opportunities for use of Registries - David Holmes Jr.

Looking Forward: New Clinical Trial Design – The FDA Perspective - Rachel Neubrander

Patient Selection for LAA Closure: The Role of Shared Decision Making - Megan Coylewright